NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro

Key Takeaways NeoGenomics launches PanTracer Pro to streamline testing for advanced solid tumors.NEO says the assay pairs DNA/RNA sequencing of 500 genes with IHC to guide therapy and trials.NeoGenomics reported Q4 sales near $190M, up 11%, and expects double-digit growth in 2026.NeoGenomics, Inc. (NEO) recently announced the availability of its new pan-solid tumor assay, PanTracer Pro, designed to help clinicians navigate increasingly complex molecular testing workflows to make informed decisions for patie ...